Li Yang, Huang Shao-liang, Wu Yan-feng, Wei Jing, Meng Ying, Zhou Dun-hua, Bao Rong
Stem Cell Research Center, The Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
Zhonghua Xue Ye Xue Za Zhi. 2005 May;26(5):269-72.
To evaluate the effects of K562-dendritic cell (DC) and Raji-DC fusion vaccines on the cytotoxicity of cord blood (CB) derived cytokine-induced killer/natural killer (CIK/NK) cells.
DC and CIK/NK cells were derived from CB mononuclear cells. CB-DC were fused with inactivated K562 or Raji cells by PEG to form K562 or Raji-DC fusion vaccine. The CIK/NK cells stimulated by different co-culture antigens were three groups: K562-DC or Raji-DC fusion vaccine group, inactivated K562 or Raji plus DC group, and CB-DC alone group. The cytotoxicity of CIK/NK cells stimulated by different co-culture antigens was measured by MTT test.
All the antigens used for stimulation could enhance the cytotoxicity of CB-CIK/NK cells, with no specificity difference. At 20:1 effector-target ratio, the cytolytic activities of K562-DC and Raji-DC fusion vaccine groups against Raji cells were (75.44 +/- 4.19)% and (81.33 +/- 4.18)% respectively (P < 0.05); and that of inactivated K562 + DC and Raji + DC group against Raji cells were (73.12 +/- 4.22)% and (80.49 +/- 4.27)%, respectively (P < 0.01). There was no significant difference in the cytotoxicity to K562 cells between the two fusion vaccine groups (P > 0.05). The cytotoxicity of CB-CIK/NK cells immunized by Raji cells was higher than that by K562 cells. In CIK/NK cells co-stimulated by the same tumor antigen, there was no significant difference in the cytotoxicity between DC fusion vaccine group and inactivated cells plus DC group to different tumor cells.
The cytotoxicity of CB-CIK/NK cells to tumor cells was not specific. There was no significant difference in the cytotoxic activity of CB-CIK/NK cells between the DC fusion vaccine group and inactivated cells plus DC group.
评估K562 - 树突状细胞（DC）和Raji - DC融合疫苗对脐血（CB）来源的细胞因子诱导的杀伤细胞/自然杀伤细胞（CIK/NK）细胞毒性的影响。
DC和CIK/NK细胞来源于CB单个核细胞。CB - DC通过聚乙二醇（PEG）与灭活的K562或Raji细胞融合，形成K562或Raji - DC融合疫苗。由不同共培养抗原刺激的CIK/NK细胞分为三组：K562 - DC或Raji - DC融合疫苗组、灭活的K562或Raji加DC组以及单独的CB - DC组。通过MTT试验检测不同共培养抗原刺激的CIK/NK细胞的细胞毒性。
所有用于刺激的抗原均可增强CB - CIK/NK细胞的细胞毒性，无特异性差异。在效应细胞与靶细胞比例为20:1时，K562 - DC和Raji - DC融合疫苗组对Raji细胞的溶细胞活性分别为（75.44±4.19）%和（81.33±4.18）%（P < 0.05）；灭活的K562 + DC和Raji + DC组对Raji细胞的溶细胞活性分别为（73.12±4.22）%和（80.49±4.27）%（P < 0.01）。两个融合疫苗组对K562细胞的细胞毒性无显著差异（P > 0.05）。Raji细胞免疫的CB - CIK/NK细胞的细胞毒性高于K用562细胞免疫的。在由相同肿瘤抗原共刺激的CIK/NK细胞中，DC融合疫苗组和灭活细胞加DC组对不同肿瘤细胞的细胞毒性无显著差异。
CB - CIK/NK细胞对肿瘤细胞的细胞毒性无特异性。DC融合疫苗组和灭活细胞加DC组的CB - CIK/NK细胞的细胞毒性活性无显著差异。
